Laboratory Corp. of America Holdings | Cash Flow

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
575
513
439
733
1,274
884
Depreciation, Depletion & Amortization
230
246
458
499
533
552
Other Funds
5
2
13
10
4
83
Funds from Operations
893
815
1,011
1,390
1,417
1,376
Changes in Working Capital
75
76
29
214
43
70
Net Operating Cash Flow
819
739
982
1,176
1,459
1,305
Capital Expenditures
202
204
256
279
315
Sale of Fixed Assets & Businesses
1
1
1
31
6
Purchase/Sale of Investments
1
11
4
1
36
Net Investing Cash Flow
360
350
3,995
796
2,229
Issuance/Reduction of Debt, Net
319
44
3,073
667
900
Net Financing Cash Flow
518
201
3,185
650
632
Net Change in Cash
63
176
136
283
117
Free Cash Flow
617
536
727
897
1,147
Deferred Taxes & Investment Tax Credit
56
28
34
55
526
22
Net Assets from Acquisitions
160
159
3,736
549
1,883
Change in Capital Stock
842
154
99
27
265
Exchange Rate Effect
4
12
36
13
21

About Laboratory

View Profile
Address
358 South Main Street
Burlington North Carolina 27215
United States
Employees -
Website http://www.labcorp.com
Updated 07/08/2019
Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.